-
今开：--
昨收：--
-
今日区间：--
52周区间：--
-
成交量：--
成交额：--
-
市 值：--
市盈率：--
-
振幅：
每股收益：
成交量
董事会
- Pei Zhi Luo
- Pei Zhi Luo is the Chairman & Chief Executive Officer of Adagene, Inc., a company he founded in 2011. He is also the President, Director & Chief Technology Officer of Abmaxis, Inc., a company he founded in 2000. Dr. Luo previously worked as a Director-Biologics Technology at Merck & Co., Inc. and as a Scientist at Xencor, Inc. He received his undergraduate degree from Peking University in 1986, his doctorate degree from The University of Chicago in 1995, and his graduate degree from the Chinese Academy of Sciences in 1989.
-
- Fang Yong Du
- Fang Yong Du is currently the Director & Chief Technology Officer at Adagene, Inc. He previously worked as a Principal at Affomix Corp. Dr. Du received his undergraduate and graduate degrees from Peking University in 1991 and 1994 respectively. He also holds a doctorate degree from the California Institute of Technology, which he obtained in 2001.
-
- Man Kin Tam
- Man Kin Tam is currently the Chief Financial Officer & Director at Adagene, Inc. He is also a Member of The American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. Previously, he worked as a Project Director at Mineralogy Pty Ltd. From 2016 to 2018, he served as the Chief Financial Officer & Executive Director at Beijing Gas Blue Sky Holdings Ltd. Prior to that, he was the Chief Financial Officer at China Regenerative Medicine International Ltd. from 2015 to 2016 and at Resourcehouse Ltd. from 2010 to 2015. He also held the position of Chief Financial Officer at MiNK Therapeutics, Inc. Mr. Tam holds a graduate degree from Monash University, an undergraduate degree from Auckland University, and an MBA from the University of Western Ontario.
-
- Yiu Leung Cheung
- Yiu Leung Cheung is an Independent Non-Executive Director at Shanghai MediTrust Health Technology Group Co., Ltd. since 2025, Hua Medicine Ltd. since 2023, Beijing Mabworks Biotech Co., Ltd. since 2021, CanSino Biologics, Inc. since 2024, and Genscript Biotech Corp. since 2024. Mr. Cheung is an Independent Director at Adagene, Inc. since 2021. Mr. Cheung is a Member of the Hong Kong Institute of Certified Public Accountants. Former roles include Director & Deputy Managing Partner-Area at Ernst & Young (Asia-Pacific) Services Ltd. from 2018 to 2020, Independent Non-Executive Director at JW (Cayman) Therapeutics Co. Ltd. from 2020 to 2024, Independent Non-Executive Director at Shenzhen Edge Medical Co., Ltd., and Chief Financial Officer at Ernst & Young China Advisory Ltd. from 2009 to 2010. Education includes an undergraduate degree from the University of Lancaster in 1982 and a graduate degree from the London School of Economics & Political Science in 1983.
-
- Min Li
- Min Li is the founder of SciNeuro Pharmaceuticals, founded in 2020, holding the titles of Chief Executive Officer & Director. Current jobs include Chief Executive Officer & Director at SciNeuro Pharmaceuticals Ltd., Independent Non-Executive Director at Novotech Health Holdings Ltd. since 2021, and Independent Non-Executive Director at Laekna, Inc. since 2023. Former jobs include Independent Director at Adagene, Inc., Senior Vice President at GSK Plc from 2013 to 2019, Professor-Neuroscience at The Johns Hopkins University School of Medicine from 1993 to 2013, and Partner at Lilly Asia Ventures (Hongkong) from 2019 to 2020. Education includes an undergraduate degree from Wuhan University in 1984 and a doctorate from The Johns Hopkins University in 1991. Dr. Li is the founder.
-
- Cuong Viet Do
- Cuong Viet Do was the founder of Callidus Biopharma, Inc. (founded in 2010) and served as Chairman from 2010 to 2013. Mr. Do is the founder of Perceptivus LLC (founded in 2014) and serves as Chairman since 2014. Mr. Do is the founder of Identifor, Inc. (founded in 2014) and serves as Chairman since 2014. Mr. Do is the founder of M6P Therapeutics (founded in 2017) and serves as Chairman since 2017. Current jobs include President, Chief Executive Officer & Director at BioVie, Inc. since 2021; Chief Executive Officer & Director at Option Therapeutics, Inc.; Director at Celebrate The Children; Director at True Image Interactive, Inc.; Independent Director at Adagene, Inc. since 2022; Director at ILiAD Biotechnologies LLC; Independent Director at Curve UK Ltd. since 2021; Director at Hope Portal Services, Inc.; Director at Seneca Therapeutics, Inc. since 2023; Independent Director at Spark I Acquisition Corp. since 2021; Independent Director at Verde Bioresins Corp.; Trustee at Newark Academy; Owner at Do & Rickles Investments; Advisor at Autism Impact Fund; Member at Social Impact Partners. Former jobs include Director & Senior Partner at McKinsey & Co., Inc. from 1989 to 2006; Chief Strategy Officer & Senior Vice President at Lenovo Group Ltd. from 2006 to 2009; SVP-Corporate Strategy & Business Development at TE Connectivity Ltd. from 2009 to 2011; Director at Wuxi PharmaTech (Cayman), Inc. from 2007 to 2011; Chief Strategy Officer & Executive Vice President at Merck & Co., Inc. from 2011 to 2014; SVP-Corporate Strategy, Mergers & Acquisitions at TE Connectivity Corp. in 2013; President at Samsung Global Strategy Group; President-Global Strategy at Samsung Group from 2015 to 2021; Director at National Youth Science Foundation, Inc. Education includes undergraduate degree from Dartmouth College in 1988 and MBA from Tuck School of Business at Dartmouth in 1989.
-
- Mervyn J. Turner
- Mervyn J. Turner is the founder of PrescribeWell, Inc. He currently holds multiple director positions at Lunac Therapeutics Ltd., PharmAkea, Inc., EnGeneIC Pty Ltd., Adagene, Inc., Spinogenix, Inc., Amydis, Inc., SAB Sciences, Inc., and Excel Medical Ventures LLC. He previously held director positions at Preventice Technologies, Inc., Tunitas Therapeutics, Inc., Big Cypress Acquisition Corp., and SAB Biotherapeutics, Inc. He also served as Chief Strategy Officer and Senior Vice President at Merck & Co., Inc. and Chief Strategy Officer at Schering-Plough Corp. He was an advisor at Quaker Partners Management LP and served as Chief Strategy Officer and Senior Vice President of Worldwide Licensing at Merck Sharp & Dohme Corp. He earned a doctorate degree from The University of Sheffield.
-
- Yumeng Wang
- Yumeng Wang is currently the Director at Adagene, Inc. since 2023 and the Vice President at General Atlantic Asia Ltd. since 2017. Previously, Ms. Wang held positions as a Non-Executive Director at Biotheus, Inc. and Ocumension Therapeutics. Ms. Wang completed an undergraduate degree at The Hong Kong University of Science & Technology in 2013 and a graduate degree at the same institution in 2021.
-
- Ulf Grawunder
- Ulf Grawunder was the founder of 4-Antibody AG, founded in 2002, where the title held was Chief Scientist from 2009 to 2010. Dr. Grawunder is the founder of NBE-Therapeutics AG, founded in 2012, holding the title Director, Chief Operating & Development Officer since 2020. Dr. Grawunder is the founder of T-CURX GmbH, founded in 2017, serving as Chief Executive Officer since 2017. Current jobs include Independent Non-Executive Director at WuXi XDC Cayman, Inc., Independent Director at Adagene, Inc. since 2024, and Managing Partner at Viopas Venture Consulting GmbH since 2022. Former job includes Principal at the University of Southern California. Education includes a doctorate from the University of Basel conferred in 1994 and a graduate degree from the University of Bayreuth conferred in 1991.
-